Clinical Trial

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 8, 2020 (before its estimated June 4, 2022 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I/II, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in adult with R/R Non-Hodgkins Lymphoma in China.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-06-18.
Trial Details
NCT Number NCT04440436
Lead Sponsor Beijing Immunochina Medical Science & Technology Co., Ltd.
Collaborators: Jiangsu Simcere Pharmaceutical Co., Ltd.
Conditions NHL
Enrollment 52 participants
Start Date 2020-06-04
Primary Completion 2022-06-04 (estimated)
Study Completion 2035-06-04 (estimated)
Updated on ClinicalTrials.gov 2020-12-08